A commercial vendor received two AAV samples, one serotype 5 (AAV5) and one serotype 9 (AAV9). The two samples were generated ...

The global viral vectors and plasmid DNA manufacturing market was valued at $918.37 million in 2019, and is estimated to reach at $4,978.54 million by 2027, registering a CAGR of ...

Median OS increased from 11 to 13 months in IMNN-001 treatment group based on latest data analysis No change in IMNN-001 favorable safety profile including no reports of serious immune-related adverse ...

The phase 2 AQUAx2 study (NCT05926765) continues to enroll and dose participants at multiple sites in the U.S., Canada, and ...

FipA is a novel component required for bacteria that rely on FlhF/FlhG to properly localize their flagella to the cell pole.

Viral Vector Development MarketThe Viral Vector Development Market is set for impressive growth, with its valuation expected to rise from USD 730.7 million in 2023 to USD 4.1 billion by 2033, ...

Genetic Immunity, a leader in plasmid DNA-based immunotherapies, and VectorBuilder, a global specialist in gene delivery solutions, announced a strategic partnership to advance Genetic Immunity's ...

Next-generation sequencing allows for critical insights into gene therapy products, which can help streamline and accelerate ...

VectorBuilde & Sartorius ink strategic cooperation agreement to advance biopharmaceutical innovation: Chicago, Illinois Thursday, November 28, 2024, 11:00 Hrs [IST] VectorBuilder, ...

This valuable study reports the first characterization of the CG14545 gene in Drosophila melanogaster, which the authors name "Sakura." Acting during germline stem cell fate and differentiation, ...

The collaboration will focus on gene vector and mRNA bioprocess solutions and services ... further optimization of the development platform and commercial production of GMP-compliant mRNA, plasmid and ...